NCT03823131 2023-05-09
Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat
University of California, San Francisco
Phase 2 Terminated
University of California, San Francisco
Incyte Corporation
Incyte Corporation
University of Chicago